<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Dr. Pollyea on the Role of Maintenance Therapy in AML

Default sub title

minute read

by OncLive | April 14, 2022
placeholder

Dan Pollyea, MD, MS, associate professor, clinical director of leukemia services, University of Colorado Denver – Anschutz Medical Campus, discusses the current role of maintenance therapy in patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

Topics: Press Coverage